Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
MarketBeat on MSN

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...
Hosted on MSN

Contrarius Global Equity Fund’s thoughts on CRISPR Therapeutics’ (CRSP) gene editing therapy

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The ...
Nasdaq

CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter. The ...